BioNTech finds itself navigating a dual narrative this week, marked by a significant corporate milestone and the emergence of fresh legal headwinds. The German biotech firm has finalized its takeover of rival CureVac, a move that consolidates its position in the mRNA technology arena. Concurrently, the company, alongside partners Pfizer and Moderna, is confronting a new patent infringement lawsuit filed by Bayer.
A Landmark Deal Closes as Shares Face Pressure
The strategic consolidation within the mRNA sector reached its conclusion on Wednesday, January 7, 2026. BioNTech confirmed the completion of its acquisition of CureVac, following amendments to the articles of association and the squeeze-out of remaining minority shareholders. With this transaction, BioNTech now holds full ownership of CureVac’s operational business, and CureVac shares have been delisted from the market.
The acquisition is viewed as a direct enhancement of BioNTech’s core platform, specifically bolstering its capabilities in mRNA design and formulation. This expansion comes at a time when the company’s stock has shown sensitivity to a complex news environment. Over the past seven trading days, the share price experienced a notable pullback of more than 11 percent. It currently trades at 84.20 euros, hovering near its 50-day moving average of 85.87 euros.
Bayer Subsidiary Alleges Patent Infringement
Introducing a new layer of complexity, Bayer’s subsidiary Monsanto initiated legal proceedings on Tuesday. The lawsuit, filed in a federal court in Delaware, accuses BioNTech, Pfizer, and Moderna of intellectual property violations.
Should investors sell immediately? Or is it worth buying BioNTech?
The core allegation presents an unusual link between agricultural biotechnology and cutting-edge vaccine development. Monsanto contends that the vaccine makers utilized a stabilization method originally pioneered in the 1980s for protecting mRNA in plants, aimed at making crops more pest-resistant. The suit claims this technique was replicated to stabilize the genetic material in the COVID-19 vaccines.
A critical detail for investors is the scope of the claim: Bayer is not seeking to halt the production or distribution of the vaccines. The lawsuit is exclusively focused on securing financial compensation, though a specific monetary demand has not yet been disclosed.
Broader Context and Future Focus
This new dispute adds to a list of simmering patent conflicts that have arisen following the commercial success of COVID-19 vaccines. In 2024 alone, BioNTech’s Comirnaty vaccine generated $3.3 billion in revenue. Despite the emerging legal risks, analyst sentiment, including from firms like HC Wainwright & Co., has remained largely positive. This optimism tends to focus on the company’s development pipeline rather than the legacy products from the pandemic era.
Investor attention is now expected to shift back to operational developments. The next significant event is scheduled for March 10, 2026, when BioNTech will release its fourth-quarter and full-year 2025 financial results. Beyond detailing the financial impact of the CureVac integration, the report will likely spotlight progress within the oncology division, particularly advancements related to the antibody candidate BNT327.
Ad
BioNTech Stock: Buy or Sell?! New BioNTech Analysis from January 8 delivers the answer:
The latest BioNTech figures speak for themselves: Urgent action needed for BioNTech investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from January 8.
BioNTech: Buy or sell? Read more here...
